Markus Naumann

Prof. Markus Naumann

Department of Neurology and Clinical Neurophysiology, Academic Hospital, Klinikum Augsburg, Augsburg 86156, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Markus NaumannMarkus Naumann
Markus Naumann
ACAlastair Carruthers
Alastair Carruthers
JCJean Carruthers
Jean Carruthers
SASheena K. Aurora
Sheena K. Aurora
RZRoss Zafonte
Ross Zafonte
MBMitchell F. Brin
Mitchell F. Brin

1 June 2013 in Toxicon
Verified
Journal Article
Closed access
Markus NaumannMarkus Naumann
Markus Naumann
DDDirk Dressler
Dirk Dressler
MHMark Hallett
Mark Hallett
JJJoseph Jankovic
Joseph Jankovic
GSGiampietro Schiavo
Giampietro Schiavo
DTDaniel Truong
Daniel Truong

Verified
Journal Article
Open access
PDF file
DRDaniela Rau
Daniela Rau
MLMichael Lang
Michael Lang
AHAndreas Harth
Andreas Harth
Markus NaumannMarkus Naumann
Markus Naumann
Frank WeberFrank Weber
Frank Weber
ABAntonios Bayas
Antonios Bayas
Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.

17 May 2023 in Toxins
Verified
Journal Article
Open access
PDF file
Joseph JankovicJoseph Jankovic
Joseph Jankovic
Jean Diana Averil CarruthersJean Diana Averil Carruthers
Jean Diana Averil Carruthers
Markus NaumannMarkus Naumann
Markus Naumann
POPatricia Ogilvie
Patricia Ogilvie
TBTerry Boodhoo
Terry Boodhoo
JSJie Shen
Jie Shen
Though the formation of neutralizing antibodies (NAbs) during treatment with botulinum neurotoxin is rare, their presence may nonetheless affect the biological activity of botulinum toxin and negatively impact clinical response. The goal of this updated meta-analysis was to evaluate and characterize the rate of NAb formation using an expanded dataset composed of 33 prospective placebo-controlled and open-label clinical trials with nearly 30,000 longitudinal subject records prior to and following onabotulinumtoxinA treatment in 10 therapeutic and aesthetic indications. Total onabotulinumtoxinA doses per treatment ranged from 10 U to 600 U administered in ≤15 treatment cycles. The NAb formation at baseline and post-treatment was tested and examined for impact on clinical safety and efficacy. Overall, 27 of the 5876 evaluable subjects (0.5%) developed NAbs after onabotulinumtoxinA treatment. At study exit, 16 of the 5876 subjects (0.3%) remained NAb positive. Due to the low incidence of NAb formation, no clear relationship was discernable between positive NAb results and gender, indication, dose level, dosing interval, treatment cycles, or the site of injection. Only five subjects who developed NAbs post-treatment were considered secondary nonresponders. Subjects who developed NAbs revealed no other evidence of immunological reactions or clinical disorders. This comprehensive meta-analysis confirms the low NAb formation rate following onabotulinumtoxinA treatment across multiple indications, and its limited clinical impact on treatment safety and efficacy.

1 July 2023 in Medicine
Verified
Journal Article
Open access
NLNicholas Lowe
Nicholas Lowe
Markus NaumannMarkus Naumann
Markus Naumann
NENina Mba Eadie
Nina Mba Eadie
Hyperhidrosis (chronic excessive sweating) may substantially affect an individual’s emotional and social well-being. Therapies available before onabotulinumtoxinA were generally topical, with limited effectiveness, application-site skin reactions, and frequent, time-consuming treatments. Intradermal injection of onabotulinumtoxinA to treat sweat glands arose as a novel therapeutic approach. To develop this treatment, appropriate dosing needed to be established, and training on administration was required. Further, no previous scale existed to measure the effects of hyperhidrosis on patients’ lives, leading Allergan to develop and validate the 4-point Hyperhidrosis Disease Severity Scale (HDSS), which measures the disease’s impact on daily activities. The onabotulinumtoxinA clinical development program for hyperhidrosis included 2 double-blind, placebo-controlled pivotal trials, immunogenicity studies, long-term studies of safety and efficacy, and quality of life assessments. In Europe and North America, the primary efficacy measures were, respectively, axillary sweat production measured gravimetrically and HDSS improvement. Compared with placebo, onabotulinumtoxinA treatment significantly reduced axillary sweat production and axillary hyperhidrosis severity, as measured by a 2-point or greater reduction on the HDSS. The effects of onabotulinumtoxinA occurred rapidly, within 1 week after injection, and lasted ≥6 months. Treatment with onabotulinumtoxinA was associated with significant quality of life improvements based on Short Form-12 physical and mental component scores. The Hyperhidrosis Impact Questionnaire also indicated greater treatment satisfaction, reduced negative impact on aspects of daily life, and improved emotional well-being with onabotulinumtoxinA versus placebo. The clinical development program and subsequent clinical experience showed that onabotulinumtoxinA treatment for hyperhidrosis was well tolerated with no new safety signals, and led to greater disease awareness.

6 June 2020 in Medicina
Verified
Journal Article
Open access
PDF file
MEMichael Ertl
Michael Ertl
CMChrista Meisinger
Christa Meisinger
JLJakob Linseisen
Jakob Linseisen
SBSebastian-Edgar Baumeister
Sebastian-Edgar Baumeister
PZPhilipp Zickler
Philipp Zickler
Markus NaumannMarkus Naumann
Markus Naumann
Introduction: In Germany, stroke is the third leading cause of death, with more than 60,000 fatalities out of approximately 260,000 cases (first-ever and recurrent strokes) each year. So far, there are only a few long-term studies investigating determinants of the natural course of the disease, especially in the era of mechanical thrombectomy. Materials and Methods: The prospective single-center stroke cohort Augsburg (SCHANA) study will include about 1000 patients treated for stroke in the University Hospital of Augsburg. Patients aged 18 years or older with a confirmed diagnosis of ischemic or hemorrhagic stroke are included in the study. Information on demographic characteristics, onset of symptoms, etiologic factors, comorbidities, quality of life, invasive and non-invasive treatment, complications, and laboratory parameters are collected during a personal interview conducted during the patients’ hospital stay and via a medical chart review. About 30 mL of blood is collected from each patient, and after processing and aliquoting, all blood specimens are frozen at −80° C. The study participants will be followed-up via postal questionnaires at three and 12 months after discharge from the hospital. Furthermore, mortality follow-ups will be conducted. Cox-regression analysis will be used to estimate relative risks. Conclusion: The SCHANA study will generate comprehensive data on the long-term course of the disease. In addition to the main outcomes, recurrent events and survival, patient-oriented outcomes such as health-related quality of life and depression are the focus of the study.